Sun Pharma gains 6% on good Q3 results, Rs 5.50 per share interim dividend

Analysts had expected the revenues to grow around 6 per cent YoY and Ebitda margins expected to improve 42 bps YoY to 23 per cent

Shares of Sun Pharmaceutical Industries moved higher by 6 per cent to Rs 600, bouncing back 8 per cent from day’s low of Rs 554, after the company’s net profit more-than-doubled at Rs 1,852 crore in December quarter (Q3FY21). The company had reoported a profit of Rs 914 crore in the corresponding quarter last year.

Consolidated sales from operations grew 9.2 per cent year on year (YoY) at Rs 8,782 crore, as against Rs 8,039 crore in the corresponding quarter of the previous fiscal. Ebitda (earnings before interest, taxes, depreciation, and amortization) jumped 36.3 per cent at Rs 2,351